Tirzepatide for Weight Loss and Metabolic Health — Weight & Metabolism
FDA-approved GIP/GLP-1 dual agonist for significant weight reduction and metabolic optimization.
Overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and obesity (Zepbound). The SURMOUNT clinical trial program demonstrated exceptional weight loss (15-22% in obesity trials, up to 25.3% with long-term therapy) superior to all previous medications. SURPASS trials in diabetes showed HbA1c reductions of 1.87-2.46% with significant weight loss.
Indications
- Obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions
- Type 2 diabetes management
- Metabolic syndrome optimization
Mechanism of Action
Excess body weight impairs glucose metabolism, insulin sensitivity, and satiety hormone signaling
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Tirzepatide | 2.5 mg | Once weekly | Starting dose, minimal side effects, GI adaptation |
| Tirzepatide | 5 mg | Once weekly | First therapeutic dose, weight loss begins |
| Tirzepatide | 7.5 mg | Once weekly | Enhanced weight loss, improved metabolic markers |
| Tirzepatide | 10 mg | Once weekly | Optimal dose for most patients, 15-18% weight loss |
| Tirzepatide | 12.5-15 mg | Once weekly | Maximum dose for advanced weight loss (20-22%) |
Evidence Grade
GRADE A
Safety & Contraindications
- FDA-approved medication with extensive safety data
- Common side effects: nausea, vomiting, diarrhea (usually transient)
- Contraindicated in personal/family history of medullary thyroid carcinoma
- Requires healthcare provider supervision